Clinical Trial Enrollment Challenges: Why Sites Miss Their Goals and What Actually Fixes It
Published May 2026 · 12 min read · By Clinical Enroll
Most writing about clinical trial enrollment challenges is written for sponsors. It covers protocol design, diversity mandates, decentralized trial models, and the patient awareness gap. All real problems. None of them are yours to fix.
You run a site. You have a coordinator, a patient population, and an enrollment target written into an agreement with a sponsor who expects you to hit it. When you don't, the conversation gets uncomfortable.
This guide is written for that position: the site director, PI, or coordinator trying to close the gap between the number you committed to and the number you actually hit.
The Scale of the Problem
80%
of clinical trials fail to meet their original enrollment timelines
11%
of sites enrolled in a given trial will enroll zero patients
These are not anomalies. They are the baseline.
What gets less attention is the distribution of that failure. The sites that miss enrollment are not all under-resourced or poorly run. Many are experienced sites with qualified coordinators, established patient populations, and clean operations. They miss enrollment for structural reasons, not competence reasons.
That distinction matters. If the problem were capability, the solution would be training. But most of the sites that miss their targets are capable of hitting them. The failures come from how they select studies, how they handle referrals, and who they rely on for recruitment support.
Why the Common Explanations Miss the Point
The two most common explanations for enrollment shortfalls are patient awareness and protocol complexity. Both are real. Neither is actionable for a site.
"Patients don't know about trials" is true. Only about 2% of U.S. patients are aware that clinical trials are an option for their condition. But awareness campaigns run at the national level, not the site level. You cannot solve patient awareness from your office.
"Eligibility criteria are too strict" is also frequently true. Narrow inclusion windows, long exclusion lists, and demanding visit schedules shrink the eligible population before you enroll anyone. But the sponsor controls the protocol. You agreed to run the study with those criteria. Pointing at the protocol after missing enrollment does not change the outcome.
The explanations that are actually actionable live inside your operations: which studies you take on, how quickly you respond to leads, whether your referrals are pre-screened, and what accountability you have built into your recruitment partnerships. That is where the leverage is.
The 5 Structural Reasons Sites Miss Enrollment Targets
Committing to studies before modeling the patient population
Most sites evaluate feasibility through the sponsor's questionnaire. Those questionnaires ask about infrastructure, regulatory experience, and PI availability. They do not ask you to model your actual addressable patient population against the protocol's eligibility criteria.
The result: sites commit to enrollment targets based on general impressions of their patient volume, not on any rigorous estimate of how many eligible patients are likely to exist within reach of their location.
When the math does not work, no amount of recruitment effort fixes it. You can run ads, pull your database, and push physician referrals. If the eligible population is smaller than the target, you will miss. The fix is running the feasibility math before you sign, not after you are behind.
No pre-screening before leads reach the coordinator
Even when a site has a recruitment partner, most referral pipelines send unqualified leads directly into the coordinator's queue. The coordinator then spends hours contacting people who don't meet basic eligibility criteria.
This is expensive in two ways. It burns coordinator time that should go toward qualified patients. And it creates the experience of a high-volume, low-yield recruitment effort, which leads sites to conclude that "recruitment doesn't work" when the problem is the referral process.
A functioning pre-screening step sits between the initial inquiry and the coordinator. It filters on the criteria that will disqualify most people before they ever reach the site team. The coordinator's queue should contain only patients who have already confirmed they meet the basic inclusion requirements.
Slow referral-to-first-contact time
Response time matters more than most sites account for. Research on lead conversion consistently shows that the probability of successful contact drops sharply within the first hour of inquiry and continues declining over the following 24 hours. Clinical trial referrals behave the same way.
A patient who fills out a screening form on Monday afternoon and doesn't hear back until Wednesday is a patient who has reconsidered, forgotten, or moved on.
Most sites run a business-hours callback model. Referrals sit in an email queue until a coordinator has time. A 4-hour target for first contact is achievable at most sites without additional headcount, if the triage process is built correctly. Most sites have not built it.
Relying entirely on passive recruitment
Passive recruitment means waiting for patients to find you: database pulls, physician referrals, word of mouth, and patients who discover the trial through ClinicalTrials.gov.
These channels have a ceiling. Internal databases degrade at roughly 25% per year as contact information goes stale, patients change providers, and conditions evolve. Physician referrals depend on how much capacity the referring physician has that week.
Passive recruitment is a floor, not a ceiling. Sites that consistently hit their enrollment targets run active outreach alongside their passive channels, reaching patients in condition-specific digital environments where they actually spend time, rather than waiting for those patients to find the trial.
No accountability structure with recruitment partners
This is the most common and most costly structural failure.
The standard clinical trial recruitment model bills for activity. The vendor runs a campaign, counts referrals, reports on impressions and click-through rates, and invoices at month's end. If the site misses enrollment, the vendor has done the work they were paid to do. The site absorbs the gap.
This model creates a fundamental misalignment. The vendor is incentivized to generate referrals, not randomizations. Activity is the product. Outcomes are not guaranteed.
A real accountability structure ties the vendor's commitment to randomized patients, not activity metrics. It means a contractual enrollment number before the campaign starts, not a projection that becomes a footnote when the study closes short. Sites that demand this structure get different vendor behavior — including a real feasibility evaluation before any commitment is made.
The Feasibility Math Most Sites Skip
Before committing to an enrollment target, a site should be able to answer three questions with reasonable precision:
- 1How many people in my catchment area have this condition?
- 2Of those, how many are likely to meet the inclusion and exclusion criteria?
- 3Of those who are eligible, what percentage can be realistically reached and converted through available channels?
Most sites can answer question one with a rough estimate. Questions two and three get hand-waved.
Working through question two requires reading the protocol carefully and applying a series of reduction factors: local prevalence rate, percentage currently on treatment (or not, depending on criteria), percentage with excluded comorbidities, percentage within practical geographic range. Each factor multiplies the previous one. A condition with 500,000 diagnosed patients in the U.S. can produce a catchment of a few hundred eligible candidates within 30 miles of a site once real protocol criteria are applied.
Question three requires knowing your referral-to-enrollment conversion rate from previous studies, or working from published benchmarks. A typical digital recruitment funnel converts roughly 1 in 30 to 1 in 50 ad responses into a randomized patient, depending on indication complexity.
Working through this math takes a few hours before you commit. Skipping it can cost months of underperformance after you sign.
Free Resource
Get a structured feasibility report for your study
An enrollment feasibility report covers the addressable patient population, a screen-to-randomization funnel projection, competitive landscape in your geography, and a channel-level assessment — specific to your NCT number and site location. Free during early access. Delivered in 24 hours.
Request a Free ReportWhat the Numbers Actually Look Like
The financial case for getting enrollment right becomes clear once you run the math.
For Phase III trials, sponsors pay sites between $5,000 and $20,000 per randomized patient in grant payments, depending on indication and protocol complexity. A Journal of Clinical Oncology analysis of a Phase III randomized placebo-controlled trial found an average of approximately $6,100 per enrolled subject, with a range from $2,100 to $19,300. Phase II trials typically run higher: $15,000 to $40,000 per patient, reflecting the greater procedural burden and smaller patient populations at that stage (ProRelix Research, Sofpromed).
Those are the revenue numbers. Now look at the cost side.
Phase III — vTv Therapeutics T1D
$2,500 CPP
5 randomized patients · $12,500 investment
Est. site revenue: $40,000–$100,000
Read the case studyPediatric Vaccine — Blue Lake Biotechnology
$1,714 CPP
7 randomized patients · $12,000 investment
Est. site revenue: $21,000–$70,000
Read the case studyThe math is not complicated. What is missing for most sites is a reliable way to access it: a recruitment partner who commits to an outcome before the campaign starts, not after the invoice is submitted.
A Practical Framework for Fixing Enrollment at Your Site
Run feasibility before committing.
Before you sign an enrollment agreement, model your addressable patient population against the protocol's eligibility criteria. If the math does not support the target, negotiate the number or pass on the study. Committing to a number you cannot hit does not help your relationship with the sponsor.
Pre-screen before referral.
Every referral that reaches your coordinator should have already passed a basic eligibility filter. A pre-screening questionnaire does not need to be complex. It needs to filter on the criteria that disqualify most candidates, so your coordinator's time goes toward people who might actually enroll.
Set a speed-to-contact target.
Decide on a maximum response time for new referrals and build your process around it. Under four hours is achievable for most sites without additional headcount. Over 24 hours is a conversion problem you do not have to accept.
Demand outcome commitments from partners, not activity reports.
When evaluating recruitment vendors, ask one question before any others: will you put a specific number of randomized patients in the engagement agreement? If the answer is no, the vendor's incentives are not aligned with yours. How Clinical Enroll works is built around this premise. Every engagement starts with a feasibility evaluation. If the patient population, protocol, and geography support a commitment, it goes into the contract. If they don't, we say so before any money changes hands.
Track cost per randomized patient as your primary recruitment metric.
Referral volume, lead count, and click-through rates are activity metrics. Cost per randomized patient tells you what your recruitment spend is actually worth. Track it across every campaign, compare it against your per-patient site fee, and use it to evaluate every partner and channel you work with. An outcome guarantee is only meaningful when CPP is the unit of measurement both parties are working toward.
The Underlying Shift
Clinical trial enrollment challenges are real and they are persistent. Most of the solutions discussed at the industry level address problems that individual sites cannot control.
What sites can control: which studies they take on, how they handle referrals, how fast they respond, and what they demand from recruitment partners.
A site that runs feasibility math before committing, pre-screens leads before they reach the coordinator, responds within four hours, and works with a partner under a contractual randomization commitment is not a typical site. It is also not a site that misses its enrollment target.
Sources: Journal of Clinical Oncology — per-patient site fee benchmarks for Phase III trials; ProRelix Research, Sofpromed — phase-by-phase grant payment ranges; industry-reported clinical trial enrollment failure rates (80% miss timelines; 11% of sites enroll zero patients).
Find out if your study qualifies for a contractual enrollment commitment.
Not every study is a fit. Clinical Enroll runs a feasibility evaluation before extending any commitment. If your protocol, patient population, and geography support it, you receive a campaign proposal with a contractual outcome guarantee.
Check if your study qualifiesAll campaigns developed for IRB review and deployed in accordance with FDA guidance on clinical trial advertising.